Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Alcon Research, LLC, VMI Option Merger Sub, Inc., and LENSAR, Inc. entered into a termination and mutual release agreement dated March 16, 2026. The parties mutually elected to terminate the March 23, 2025 merger agreement under Section 7.1(a), and the merger agreement was terminated in its entirety.
The termination is effective immediately upon execution and is described as irrevocable. The agreement provides that LENSAR is permitted to keep and own the deposit, and Alcon waives rights and claims related to the deposit under Section 5.20 of the merger agreement. The confidentiality agreement survives the termination.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026